Participate in a Study
hello world!
Our Clinical Trial Experience

Proven Experience.
Universal Access.

Science 37 is the First & Only FDA-Inspected Direct-to-Patient Site. With more than a decade of experience, our model has supported over 200 clinical trials across Phases I–IV and observational studies.

Our Experience By the Numbers

Trusted for Over 10 Years in Direct-to-Patient Clinical Trial Delivery

200+
Clinical Trials

Conducted across Phases I–IV and Observational.

14,000+
In-Home Visits

Delivered directly to participants across the US, from standard to complex clinical assessments.

Five Phase 3
FDA Inspections

Successfully completed with zero Forms 483s issued.

Validated by the Tufts Center for the
Study of Drug Development

Trusted for Over 10 Years in Direct-to-Patient Clinical Trial Delivery

6x
More Enrollment

Compared to traditional industry
site benchmarks.

86.3%
Completion Rate

Improving participant retention.

121
Days Faster

From First Patient First Visit
to Database Lock.

Explore how we can accelerate enrollment velocity and
optimize patient reach for your clinical study.

Connect with Our Team

Proven Track Record of High-Quality Execution

Innovative trial delivery requires uncompromising quality. Science 37 sets the industry standard for direct-to-patient quality assurance and regulatory compliance.

The First & Only
FDA-Inspected
Direct-to-Patient Site

Five Phase 3 Trials Inspected by the FDA
between February 2024 and October 2025

Consistent "No Action Indicated" (NAI) Classifications
the Highest Possible Classification

Zero Form 483s Issued
with No Objectionable Conditions or Practices Identified

Deep Therapeutic Expertise
We support complex clinical assessments across a broad spectrum of indications, leveraging our national network of broadly-licensed Investigators and in-house, mobile Research-Grade Nurses.
Cardiovascular
7 Trials
Central Nervous System
29 Trials
Dermatology
19 Trials
Endocrinology
25 Trials
Gastroenterology
19 Trials
Hepatology
10 Trials
Immunology
12 Trials
Infectious Disease
19 Trials
Oncology
19 Trials
Pediatrics
22 Trials
Rare Disease
37 Trials
Respiratory
16 Trials
Download Our Experience Fact Sheet
FDA Inspected & Approved

Delivering 47% of Total U.S. Enrollment in a
Pivotal Phase 3 Primary Biliary Cholangitis Trial

High-frequency site visits put trial participants at risk of dropping out. Science 37 mitigated this by transitioning at-risk individuals to at-home participation. The strategy achieved an 82% retention rate in Part A, successfully reaching the critical milestone for evaluating the investigational drug's initial effects compared to placebo.
Enrolled
47%
of Total U.S. Study Participants
82%
Retention Rate
in patients transferred from traditional sites who were at risk of drop out
11x
Faster Enrollment
compared to traditional sites despite joining the trial 6 months later
See how we achieved similar outcomes across Respiratory,
Cardiology, CNS, and other therapeutic areas.
View More Case Studies

Peer-Reviewed Data Proves Our Site Outperforms Traditional Benchmarks Across Key Clinical Metrics.

Science 37 vs. Industry Benchmarks
Disclaimer: The information presented reflects Science 37’s experience and observations across studies utilizing its direct-to-patient clinical trial model. Certain performance metrics referenced herein are based on a retrospective analysis conducted jointly by Science 37 and the Tufts Center for the Study of Drug Development (Tufts CSDD) and should not be interpreted as guarantees of future performance or outcomes. Individual study results may vary significantly based on protocol design, therapeutic area, patient population, sponsor requirements, operational considerations, and other factors.

Case Studies: Science 37 in Action

Asthma

Delivering 28% of Total Enrollment for a Phase 3 Respiratory Trial

FDA Inspected

Science 37 was the top enrolling site, contributing 28% of total enrolled patients over a 15-month window. Science 37 enrolled 44 patients per month, demonstrating an enrollment velocity 22x greater than traditional brick-and-mortar sites (averaging only 2 patients per month), and reducing the study’s overall time-to-target enrollment.

View the Case Study
Fragile X Syndrome

Delivering 25% of Total Enrollment for a Phase 3 Rare Disease Trial

Science 37 was the top enrolling site, contributing 25% of all randomized patients nationwide. Through its Direct-to-Patient Site, which proved well-suited for this hard-to-enroll, rare disease population, including pediatric patients, Science 37 achieved a 94% patient retention rate.

View the Case Study
Vascular Ehlers-Danlos Syndrome (vEDS)

Enrolling 100% of Total Participants for a Phase 3 Rare Cardiology Trial

Science 37 enrolled all study participants across 19 U.S. states as a single Direct-to-Patient Site, successfully managing a difficult-to-enroll population with a rare genetic disorder, limited eligible patients, broad geographic dispersion, and a complex, closely monitored, long-duration (40 months with OLE) protocol.

View the Case Study
Explore More Examples of Our Site in Action

Indication Experience

Arteriovenous Fistula
Atrial Fibrillation (AFib)
Atrial Fibrillation (AFib) at Risk of Stroke
Pediatric Hypertension
Pulmonary Arterial Hypertension
Vascular Ehlers-Danlos Syndrome (vEDS)

Acute Migraine
Alzheimer's
Bipolar Depression
Cluster Headache
Epilepsy
Fragile X Syndrome (FXS)
GM2 Gangliosidosis
Huntington's Disease
Idiopathic Hypersomnia
Major Depressive Disorder (MDD)

Migraine
Multiple Sclerosis
Narcolepsy
nOH in Multiple System Atrophy
Parkinson's Disease
Rare Neurodevelopmental Disorder
Restless Leg Syndrome
Seizure
Spinal Muscular Atrophy
22q11 Deletion Syndrome (Pediatric)

Acne Vulgaris
Alopecia
Epidermolysis Bullosa
Face and Neck Atopic Dermatitis
Herpes Labialis

Moderate Acne
Moderate to Severe Atopic Dermatitis
Netherton Syndrome
Psoriasis
Severe Acne

Classic Congenital Adrenal Hyperplasia (CAH)
Congenital Adrenal Hyperplasia (CAH)
Classical Homocystinuria (HCU)
Diabetes (Type 1 and Type 2)
Diabetes (Type 2 Obesity)

Hypoparathyroidism
Phenylketonuria (PKU)
Prader-Willi Syndrome (PWS)
Severe Hypertriglyceridemia (SHTG)
Uncontrolled Hypertension and Suppressed Plasma Renin Activity

Celiac Disease
Cholestatic Pruritus
Cholestatic Pruritus Due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
Congenital Sucrase-Isomaltase Deficiency
Diabetic Gastroparesis

Eosinophilic Esophagitis
Nonalcoholic Fatty Liver Disease
Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Short Bowel Syndrome and Intestinal Failure

Benign Hematologic Disorders
Severe Hemophilia A
Sickle Cell Disease
Von Willebrand Disease

Chronic Granulomatous Disease
Tuberous Sclerosis Complex

COVID-19
COVID-19 Mitigation
COVID-19 Prophylaxis
COVID-19/Immunocompromised Prevention
COVID-19 Vaccine
Human Immunodeficiency Virus (HIV)
Mycobacterium Infections, Nontuberculous

Achondroplasia
Gout
Knee Osteoarthritis
Osteoarthritis of the Knee
Rheumatology Basket Study
Tophaceous Gout

ALK-positive Non–Small Cell Lung Cancer Tumors
Chronic Myeloid Leukemia – Chronic Phase
Lung Cancer
Solid Tumors
Unspecified Cancer

Age-related Macular Degeneration (AMD)
Wet Age-related Macular Degeneration (AMD)

Asthma
Breathing Disorders
Chronic Obstructive Pulmonary Disease (COPD)
Idiopathic Pulmonary Fibrosis (IPF)
Pulmonary/Respiratory Complications in Patients with Neuromuscular Disease (NMD)
Refractory Chronic Cough (RCC)

Chronic Kidney Disease (CKD)
Diabetic Kidney Disease (DKD)
Diabetic Nephropathy
Distal Renal Tubular Acidosis (dRTA)
Focal Segmental Glomerulosclerosis (FSGS)

Breast Cancer
Postpartum Depression

Get in touch with our specialists to discuss how our model can accelerate enrollment velocity and optimize patient reach for your clinical study.

Connect with our team to explore how we can enhance patient access and enrollment for your trial.

© 
2026
 Science 37 | All Rights Reserved
chevron-down